stockrowStoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −65.7%
- Free cash flow
- −114.9%
Quarter to September 2026, against a year earlier
Follow STOK
Alert me
Stoke Therapeutics, Inc. (STOK) EV/Sales
As of 6 November 2026, Stoke Therapeutics, Inc. (STOK) trades at a EV/Sales of 52.8×. Over the past ten years it has ranged from −7.3× (September 2023) to 80.5× (June 2024); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.6× | (16.53%) |
| FY2024 | 10.4× | 61.25% |
| FY2023 | 6.4× | (35.71%) |
| FY2022 | 10.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 51.7× | (23.63%) |
| Jun 2026 | 67.7× | 26.99% |
| Mar 2026 | 53.3× | 516.28% |
| Dec 2025 | 8.6× | 57.51% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MAZE Maze Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 0.9× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.7× |
| AGIO Agios Pharmaceuticals, Inc. compare | 7.9× |
| ZBIO Zenas BioPharma, Inc. compare | 23.5× |
| GENB Generate Biomedicines, Inc. compare | 37.2× |
| STOK Stoke Therapeutics, Inc. | 52.8× |
| ABSI Absci Corporation compare | 896× |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)